Positive News SentimentPositive NewsNASDAQ:VRCA Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis $1.46 -0.05 (-3.31%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Verrica Pharmaceuticals Stock (NASDAQ:VRCA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get VRCA alerts:Sign Up Key Stats Today's Range$1.43▼$1.5350-Day Range$1.11▼$5.2752-Week Range$1.04▼$11.41Volume321,531 shsAverage Volume438,037 shsMarket Capitalization$61.93 millionP/E RatioN/ADividend YieldN/APrice Target$11.75Consensus RatingModerate Buy Company OverviewVerrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.Read More… Trump or Kamala? It may come down to this strange twist… (Ad)Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? To uncover the full story and learn how you can potentially profit from it...watch my new documentary here. Verrica Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks90th Percentile Overall ScoreVRCA MarketRank™: Verrica Pharmaceuticals scored higher than 90% of companies evaluated by MarketBeat, and ranked 138th out of 1,013 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingVerrica Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageVerrica Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Verrica Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($1.58) to ($0.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verrica Pharmaceuticals is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verrica Pharmaceuticals is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerrica Pharmaceuticals has a P/B Ratio of 3.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Verrica Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.92% of the float of Verrica Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVerrica Pharmaceuticals has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verrica Pharmaceuticals has recently increased by 11.69%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerrica Pharmaceuticals does not currently pay a dividend.Dividend GrowthVerrica Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.67 Percentage of Shares Shorted13.92% of the float of Verrica Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverVerrica Pharmaceuticals has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verrica Pharmaceuticals has recently increased by 11.69%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News SentimentN/A News SentimentVerrica Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.Search InterestOnly 3 people have searched for VRCA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows8 people have added Verrica Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Verrica Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $408,986.00 in company stock.Percentage Held by Insiders42.60% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verrica Pharmaceuticals' insider trading history. Receive VRCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address VRCA Stock News HeadlinesVerrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ...October 9, 2024 | finance.yahoo.comNeedham Downgrades Verrica Pharmaceuticals (VRCA)October 5, 2024 | msn.comMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.October 18, 2024 | Paradigm Press (Ad)Verrica Pharmaceuticals announces workforce reductionOctober 3, 2024 | uk.investing.comVerrica Pharmaceuticals to lay off about half of its staff in restructuringOctober 3, 2024 | bizjournals.comBrookline Capital Downgrades Verrica Pharmaceuticals (VRCA)October 3, 2024 | msn.comNeedham downgrades Verrica Pharmaceuticals (VRCA) to a HoldOctober 3, 2024 | markets.businessinsider.comVerrica downgraded to hold by Needham, cash position citedOctober 3, 2024 | msn.comSee More Headlines VRCA Stock Analysis - Frequently Asked Questions How have VRCA shares performed this year? Verrica Pharmaceuticals' stock was trading at $7.32 on January 1st, 2024. Since then, VRCA shares have decreased by 80.1% and is now trading at $1.46. View the best growth stocks for 2024 here. How were Verrica Pharmaceuticals' earnings last quarter? Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.06. The company earned $5.18 million during the quarter, compared to analyst estimates of $4.70 million. Verrica Pharmaceuticals had a negative trailing twelve-month return on equity of 591.84% and a negative net margin of 625.06%. When did Verrica Pharmaceuticals IPO? Verrica Pharmaceuticals (VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO. Who are Verrica Pharmaceuticals' major shareholders? Verrica Pharmaceuticals' top institutional shareholders include Creative Planning (0.04%). Insiders that own company stock include Paul B Manning, Perceptive Advisors Llc, Ted White, Joe Bonaccorso and Christopher G Hayes. View institutional ownership trends. How do I buy shares of Verrica Pharmaceuticals? Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Verrica Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verrica Pharmaceuticals investors own include Meta Platforms (META), Paycom Software (PAYC), Walt Disney (DIS), uniQure (QURE), Marathon Oil (MRO), Centrus Energy (LEU) and Clean Energy Fuels (CLNE). Company Calendar Last Earnings8/14/2024Today10/17/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VRCA CUSIPN/A CIK1660334 Webwww.verrica.com Phone(434) 453-3300FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$11.75 High Stock Price Target$14.00 Low Stock Price Target$10.00 Potential Upside/Downside+704.8%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,000,000.00 Net Margins-625.06% Pretax Margin-625.06% Return on Equity-591.84% Return on Assets-100.16% Debt Debt-to-Equity Ratio29.58 Current Ratio2.36 Quick Ratio2.23 Sales & Book Value Annual Sales$13.91 million Price / Sales4.45 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book3.11Miscellaneous Outstanding Shares42,420,000Free Float24,492,000Market Cap$61.93 million OptionableOptionable Beta1.45 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:VRCA) was last updated on 10/18/2024 by MarketBeat.com Staff From Our PartnersDon’t Buy Another Stock Until Reading This…Buying stocks in today's market is a gamble… Unless you're using the right proven strategy! During my up...Unstoppable Prosperity | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.